The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
the trials that we use to identify these numerical amounts that the drugs improve survival are not average americans off the street with the cancer they're really carefully curated populations they're often 10 years younger than average cancer patients they don't have the same range of comorbidities they don't have as much diabetes they're not as overweight they don't have cardiovascular disease they don't have renal dysfunction they're younger healthier
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.